Biomea Fusion announced that three abstracts on its investigational diabetes drug icovamenib will be presented at the American Diabetes Association's 86th Scientific Sessions in June 2026. The data highlights icovamenib's potential to improve beta cell function and metabolic health in both type 1 and type 2 diabetes patients. Icovamenib is an oral menin inhibitor in Phase 2 trials, aiming to restore insulin production by targeting beta cell dysfunction. These presentations could advance understanding of new treatment options for diabetes management.
Moment Factory and Mitsui Fudosan have formed a long-term strategic partnership to develop large-scale immersive fan experiences, including a new Pokémon attraction set to launch in Europe in spring 2027. This collaboration combines Moment Factory's ...
FCCE, the majority shareholder of Installux, has agreed to acquire 6.38% of Installux shares from Amiral Gestion at €500 per share, totaling €8.93 million. Following this acquisition, FCCE will hold 87.45% of Installux's capital and voting rights. FC...
Toll Brothers announced a new luxury home community called Toll Brothers at West Park in Ashburn, Virginia, located in the Brambleton neighborhood. The community will feature modern single-family homes with 3 to 5 bedrooms, up to 3,300 square feet, a...
The Nasdaq 100 index surpassed 30,000 points during Tuesday's session, led by a strong rally in semiconductor stocks, especially Micron Technology which surged 18%. This rally was fueled by rising expectations for AI-related spending, with UBS raisin...
Hyliion's stock surged to a 52-week high following its partnership with the U.S. Navy to test its KARNO power system on an autonomous naval vessel. The company reported better-than-expected Q1 results, with revenue of $2.83 million and a smaller loss...
